BOTHELL, Wash., Dec. 14 CellCyte GeneticsCorporation (the "Company") (OTC Bulletin Board: CCYG) has moved from itsformer facilities in Kirkland, Washington and combined all of its corporateand administrative, R&D, imaging, manufacturing and support operations intoits now state-of-the-art research facilities and new corporate headquarters inthe Seattle-area city of Bothell, Washington.
The Company took on the 26,500 square foot facility, located in the CanyonPark biotechnology complex, in May 2007 and has completely renovated theentire site in order to accommodate CellCyte's anticipated needs for years tocome.
This facility now houses four full-scale research laboratories, threetissue culture labs for the growth and expansion of stem cells, a specialized"hot lab" for the radio-active labeling of cells, two laboratories dedicatedto device manufacturing, cell expansion and stem cell purification, adedicated nuclear imaging suite incorporating the SPECT/CT camera, a fullanimal research vivarium facility, support services and the corporate officesof CellCyte Genetics.
CellCyte Genetics will now use this facility as a staging point forworldwide operations and as the main research facility for carrying outpreclinical studies in support of its planned clinical trials, and thedevelopment of its broad pipeline of intellectual property.
As part of its scaling-up process, the Company has added Kim J. Kimbell,SPHR, CCP, as the new Head of Human Resources for CellCyte Genetics Corp.
Kim Kimbell was formerly Director of Human Resources for MDS Pharma(Formerly Skeletech, Inc.) a Seattle-area Clinical Research Organization,which she helped grow from start-up to the company's successful acquisition.She was Human Resources Manager for Zymogenetics, Inc., another growingSeattle-based biotech firm, where she was responsible for new hires and staffrequirements for that company's rapidly growing employee roster.
Ms. Kimbell joins CellCyte in order to effectively manage a major increasein staffing needs and to attract a high caliber of key personnel as theCompany occupies its new facility and approaches toxicology studies and aplanned clinical trial.
"I have to hand it to our excellent team," states Gary Reys, Chairman andCEO. "They have done an outstanding job in putting these new facilities inplace in a relatively short period of time. We have been able to create ashowcase for biotechnology research and product development at about the halfthe cost of many peer biotech companies."
"With our research teams, support staff and management now in one state-of-the-art facility, we can focus all efforts on completing preclinicalinvestigations on our lead indication; delivering adult stem cells to heal theheart. That's what this is all about."
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emergingbiotechnology company engaged in the principle business of the discovery,development and commercialization of breakthrough stem cell enablingtherapeutic products.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM ISDEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, ASAMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934,AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL,ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS,PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THEHISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWSRELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKSAND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROMANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCHSTATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INC